Document:

Exhibit 4.1

 

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase
Agreement, dated on and as of the date set forth on the signature page hereto (this “Agreement”), is made between
Transgenomic, Inc., a Delaware corporation (the “Company”), the undersigned purchaser(s) (each a “Purchaser”
and collectively, the “Purchasers”) and each assignee of a Purchaser who becomes a party hereto.

 

WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act of 1933, as amended
(the “Securities Act”) and Regulation D promulgated thereunder, the Company desires to offer, issue and sell
to the Purchasers (the “Offering”), and the Purchasers, severally and not jointly, desire to purchase from the
Company, shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common
Stock”), and 5.5-year warrants to purchase shares of Common Stock (the “Warrants”), with an exercise
price of $4.00 per share. The Shares and the Warrants are collectively referred to herein as the “Securities”.

 

NOW, THEREFORE,
in consideration of the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which is hereby acknowledged, the Company and each of the Purchasers agree as follows:

 

		A.	Subscription

 

(1)              
Subject to the conditions to closing set forth herein, each Purchaser hereby irrevocably subscribes for and agrees to purchase
Securities for the aggregate purchase price set forth on the signature page of such Purchaser hereto (the “Subscription
Amount”). The Securities to be issued to a Purchaser hereunder shall consist of (i) Shares in an amount equal to the
quotient of (x) the Subscription Amount, divided by (y) the Offering Price, rounded down to the nearest whole number, and (ii)
a Warrant to purchase such number of shares of Common Stock to be determined based on a ratio of one (1) share of Common Stock
for every two (2) Shares purchased hereunder. The aggregate amount of Securities to be issued pursuant to the Offering shall not
exceed 1,250,000 Shares and Warrants to purchase 625,000 shares of Common Stock, plus Warrants to purchase up to 37,500 shares
of Common Stock to one or more “finders” in connection with the Offering. The Company shall allocate the Subscription
Amount between the Shares and the Warrants prior to the Closing and provide notice to the Purchasers of such allocation.

 

(2)              
For purposes of this Agreement, the “Offering Price” shall be $ 3.25.

 

(3)              
As soon as possible after the date hereof, the Company shall hold the closing of the Offering (the “Closing”).

 

(4)              
Prior to the Closing, each Purchaser shall deliver the applicable Subscription Amount by check payable to the escrow account
set forth on Schedule A or by wire transfer to such escrow account in accordance with the wire transfer instructions set
forth on Schedule A, and such amount shall be held in the manner described in Paragraph (5) below.

 

    	 

    	 

    

 

(5)              
All payments for Securities made by the Purchasers will be deposited as soon as practicable for the undersigned’s
benefit in an escrow account. Any interest earned on such payments shall revert back to the escrow agent and shall be used to offset
the escrow account fees. Payments for Securities made by the Purchasers will be returned promptly, without interest or deduction,
if, or to the extent, the undersigned’s subscription is rejected or the Offering is terminated for any reason.

 

(6)              
Upon receipt by the Company of the requisite payment for all Securities to be purchased by the Purchasers whose subscriptions
are accepted, the Company shall, at the Closing: (i) irrevocably instruct Wells Fargo Shareowner Services, the Company’s
transfer agent, to issue and deliver to each Purchaser stock certificates representing the shares of Common Stock purchased under
this Agreement; (ii) issue and deliver, within 3 trading days after the Closing date, to each Purchaser a Warrant to purchase such
number of shares of Common Stock calculated in accordance with Paragraph (1) above; (iii) deliver to the Purchasers a certificate
stating that the representations and warranties made by the Company in Section C of this Agreement were true and correct in all
material respects when made and are true and correct in all material respects on the date of Closing relating to the Securities
subscribed for pursuant to this Agreement as though made on and as of the Closing date (provided, however, that representations
and warranties that speak as of a specific date shall continue to be true and correct as of the Closing with respect to such date);
and (iv) cause to be delivered to the Purchasers an opinion of Paul Hastings LLP substantially in the form of Exhibit A
hereto and reasonably acceptable to counsel for the Purchasers.

 

(7)              
Each Purchaser acknowledges and agrees that this Agreement shall be binding upon such Purchaser upon the execution and delivery
to the Company of such Purchaser’s signed counterpart signature page to this Agreement unless and until the Company shall
reject the subscription being made hereby by such Purchaser.

 

(8)              
Each Purchaser agrees that the Company may reduce such Purchaser’s subscription with respect to the number of Shares
and Warrants to be purchased without any prior notice or further consent by such Purchaser. If such a reduction occurs, the part
of the Subscription Amount attributable to the reduction shall be promptly returned, without interest or deduction.

 

(9)              
Each Purchaser acknowledges and agrees that the purchase of Shares and Warrants by such Purchaser pursuant to the Offering
is subject to all the terms and conditions set forth in this Agreement.

 

		B.	Representations and Warranties of the Purchaser

 

    Each of the Purchasers, severally and not
jointly, hereby represents and warrants to the Company and agrees with the Company as follows:

 

    	2

    	 

    

 

(1)              
The Purchaser has been furnished with and has carefully read the Company’s filings with the Securities and Exchange
Commission (“the SEC”), this Agreement and the form of Warrant attached hereto as Exhibit B (collectively
the “Offering Documents”), and is familiar with and understands the terms of the Offering. Specifically, and
without limiting in any way the foregoing representation, the Purchaser has carefully read and considered (i) the Company’s
financial statements included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2013, as
amended (the “2013 Form 10-K”), (ii) the subsection of the 2013 Form 10-K entitled “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” the section of the 2013 Form 10-K entitled “Item
1. Business,” (iii) the financial results contained in each of the Company’s quarterly reports on Form 10-Q for each
of the periods ended March 31, 2014 and June 30, 2014, (iv) the subsection of each such Form 10-Q entitled “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” and (v) fully understands all of the risks related
to the purchase of the Securities. The Purchaser has carefully considered and has discussed with the Purchaser’s professional
legal, tax, accounting and financial advisors, to the extent the Purchaser has deemed necessary, the suitability of an investment
in the Securities for the Purchaser’s particular tax and financial situation and has determined that the Securities being
subscribed for by the Purchaser are a suitable investment for the Purchaser. The Purchaser recognizes that an investment in the
Securities involves substantial risks, including the possible loss of the entire amount of such investment.

 

(2)              
The Purchaser acknowledges that (i) the Purchaser has had the opportunity to request copies of any documents, records, and
books pertaining to this investment and (ii) any such requested documents, records and books have been made available for inspection
by the Purchaser and the Purchaser’s attorney, accountant or other advisor(s).

 

(3)              
The Purchaser and the Purchaser’s advisor(s) have had: (i) the opportunity to ask questions of and receive answers
from representatives of the Company or persons acting on behalf of the Company concerning the Offering as the Purchaser has deemed
necessary and all such questions have been answered to the full satisfaction of the Purchaser., (ii) access to
information about the Company and its subsidiaries and their respective financial condition, results of operations, business, properties,
management and prospects sufficient to enable the Purchaser to evaluate the Purchaser’s investment, and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is
necessary to make an informed investment decision with respect to the investment. The Purchaser understands that the Purchaser’s
investment in the Securities involves a high degree of risk. The Purchaser has sought such accounting, legal and tax advice as
the Purchaser has considered necessary to make an informed decision with respect to the Purchaser’s acquisition of the Securities.

 

(4)              
The Purchaser is not subscribing for Securities as a result of or subsequent to any advertisement, article, notice or other
communication published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar,
meeting or conference whose attendees have been invited by any general solicitation or general advertising.

 

(5)              
If the Purchaser is a natural person, the Purchaser has reached the age of majority or equivalent status in the jurisdiction
in which the Purchaser resides. Each Purchaser has adequate means of providing for the Purchaser’s current financial needs
and contingencies, is able to bear the substantial economic risks of an investment in the Securities for an indefinite period of
time, has no need for liquidity in such investment and can afford a complete loss of such investment.

 

    	3

    	 

    

 

(6)              
The Purchaser has sufficient knowledge, sophistication and experience in financial, tax and business matters to enable the
Purchaser to utilize the information made available to the Purchaser in connection with the Offering, to evaluate the merits and
risks of an investment in the Securities to make an informed investment decision with respect to an investment in the Securities
on the terms described in the Offering Documents, and has so evaluated the merits and risks of such investment.

 

(7)              
The Purchaser will not sell or otherwise transfer the Securities without registration under the Securities Act of 1933,
as amended (the “Securities Act”) and applicable state securities laws or an applicable exemption therefrom.
The Purchaser acknowledges that neither the offer nor sale of the Securities has been registered under the Securities Act or under
the securities laws of any state. The Purchaser represents and warrants that the Purchaser is acquiring the Securities in the ordinary
course of business for the Purchaser’s own account, for investment and not with a view toward resale or distribution within
the meaning of the Securities Act. The Purchaser has not offered or sold the Securities being acquired nor does the Purchaser have
any present intention, or agreement, plan or understanding, directly or indirectly, with any person to sell, distribute or otherwise
dispose of such Securities (or any securities which are derivatives thereof) either currently or after the passage of a fixed or
determinable period of time or upon the occurrence or non-occurrence of any predetermined event or circumstances. The Purchaser
is aware that (i) the Securities are not currently eligible for sale in reliance upon Rule 144 promulgated under the Securities
Act and (ii) the Company has no obligation to register the Securities subscribed for hereunder, except as provided in Section E
hereof. The Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business
that would require the Purchaser to be so registered as a broker-dealer.

 

(8)              
The Purchaser acknowledges that the certificate(s) representing the Shares, the Warrants and, upon the exercise of the Warrants,
the shares of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”), be stamped or otherwise
imprinted with a legend substantially in the following form:

 

NEITHER THESE SECURITIES
NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED] [THESE SECURITIES HAVE NOT BEEN REGISTERED]
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

    	4

    	 

    

 

Certificates evidencing
the Shares and the Warrant Shares shall not be required to contain such legend or any other legend (i) following any sale of such
Shares or Warrant Shares pursuant to Rule 144, provided that neither the transferor nor the transferee is an affiliate of the Company
as defined therein), or (ii) if such Shares or Warrant Shares are eligible for sale under Rule 144 without the requirement for
the Company to be in compliance with the current public information required under Rule 144 as to such securities and without volume
or manner-of-sale restrictions or have been sold pursuant to the Registration Statement (as hereafter defined) and in compliance
with the obligations set forth in Section E(6), below, or (iii) such legend is not required under applicable requirements of the
Securities Act (including judicial interpretations and pronouncements issued by the Staff of the Securities and Exchange Commission),
in each such case (i) through (iii) to the extent reasonably determined by the Company’s legal counsel. At such time and
to the extent a legend is no longer required for the Shares or Warrant Shares, the Company will use its best efforts to no later
than five (5) trading days following the delivery by a Purchaser to the Company or the Company’s transfer agent of a legended
certificate representing such Shares or Warrant Shares (together with such accompanying documentation or representations as reasonably
required by counsel to the Company), deliver or cause to be delivered a certificate representing such Shares or Warrant Shares
that is free from the foregoing legend.

 

(9)              
If this Agreement is executed and delivered on behalf of a partnership, corporation, trust, estate or other entity: (i)
such partnership, corporation, trust or other entity is duly organized, validly existing and in good standing under the laws of
the jurisdiction of the Purchaser’s organization, (ii) such partnership, corporation, trust, estate or other entity has the
full legal right and power and all authority and approval required (a) to execute and deliver this Agreement and all other instruments
executed and delivered by or on behalf of such partnership, corporation, trust, estate or other entity in connection with the purchase
of the Securities by such Purchaser, and (b) to purchase and hold such Securities; (iii) the signature of the party signing on
behalf of such partnership, corporation, trust, estate or other entity is binding upon such partnership, corporation, trust, estate
or other entity; and (iv) such partnership, corporation, trust or other entity has not been formed for the specific purpose of
acquiring such Securities.

 

(10)          
If the Purchaser is a retirement plan or is investing on behalf of a retirement plan, the Purchaser acknowledges that an
investment in the Securities poses additional risks, including the inability to use losses generated by an investment in the Securities
to offset taxable income.

 

(11)          
The information contained in the purchaser questionnaire in the form of Exhibit C attached hereto (the “Purchaser
Questionnaire”) delivered by the Purchaser in connection with this Agreement is complete and accurate in all respects,
and the Purchaser, at the time the Purchaser was offered the Shares and Warrants, was, and at the date hereof is, and on the Closing
Date and on each date on which the Purchaser exercises the Warrants will be, an “accredited investor” as defined in
Rule 501 of Regulation D under the Securities Act on the basis indicated therein. The Purchaser shall indemnify and hold harmless
the Company and each officer, director or control person, who is or may be a party or is or may be threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by
reason of or arising from any actual or alleged misrepresentation or misstatement of facts or omission to represent or state facts
made or alleged to have been made by the Purchaser to the Company or omitted or alleged to have been omitted by the Purchaser,
concerning the Purchaser or the Purchaser’s authority to invest or financial position in connection with the Offering, including,
without limitation, any such misrepresentation, misstatement or omission contained in the Agreement or any other document submitted
by the Purchaser, against losses, liabilities and expenses for which the Company or any officer, director or control person has
not otherwise been reimbursed (including attorney’s fees, judgments, fines and amounts paid in settlement) actually and reasonably
incurred by the Company or such officer, director or control person in connection with such action, suit or proceeding. For the
avoidance of doubt, such indemnification shall be the several, and not joint, obligation of each Purchaser with respect to the
Purchaser’s own action or inaction as provided above.

 

    	5

    	 

    

 

(12)          
 The information contained in the selling stockholder questionnaire in the form of Exhibit D attached hereto (the
“Selling Stockholder Questionnaire”) delivered by the Purchaser in connection with this Agreement is complete
and accurate in all respects.

 

(13)          
This Agreement has been duly executed and delivered by the Purchaser and constitutes the legal, valid and binding obligation
of the Purchaser, enforceable against the Purchaser in accordance with its terms and subject to laws of general application relating
to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other
equitable remedies, and to limitations of public policy.

 

(14)          
The execution and delivery by the Purchaser of this Agreement and the consummation of the transactions contemplated hereby
will not result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court
or governmental authority to or by which the Purchaser is bound, or of any provision of the Purchaser’s organizational documents
(if applicable), and will not conflict with, or result in a breach or violation of, any of the terms or provisions of, or constitute
(with due notice or lapse of time or both) a default under, any lease, loan agreement, mortgage, security agreement, trust indenture
or other agreement or instrument to which the Purchaser is a party or by which the Purchaser is bound or to which any of the Purchaser’s
properties or assets is subject, nor result in the creation or imposition of any lien upon any of the properties or assets of the
Purchaser.

 

(15)          
Except for the issuance of Warrants to purchase up to 37,500 shares of Common Stock to one or more “finders”
in connection with the Offering as contemplated in Section A(1), no person will have, as a result of the transactions contemplated
by this Agreement, any valid right, interest or claim against or upon the Company or any Purchaser for any brokers’, finders’
or financial advisory fees or commissions pursuant to any agreement, arrangement or understanding entered into by or on behalf
of the Purchaser.

 

(16)          
The Purchaser has independently evaluated the merits of the Purchaser’s decision to purchase Securities pursuant to
this Agreement, and the Purchaser confirms that the Purchaser has not relied on the advice of any other Purchaser’s business
and/or legal counsel in making such decision. The Purchaser understands that nothing in this Agreement or any other materials presented
by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment
advice. The Purchaser has consulted such legal, tax and investment advisors as the Purchaser, in the Purchaser’s sole discretion,
has deemed necessary or appropriate in connection with the Purchaser’s purchase of the Securities.

 

    	6

    	 

    

 

(17)          
The Purchaser has not directly or indirectly engaged in any Short Sales involving the Company’s securities since the
time that it was first contacted by the Company with respect to the transactions contemplated hereby. “Short Sales”
include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange
Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps and similar
arrangements (including on a total return basis), and sales and other transactions through non-US broker dealers or foreign regulated
brokers. Notwithstanding the foregoing, in the case of a Purchaser that is or is part of a multi-managed investment vehicle (a
“Fund”) whereby separate portfolio managers manage separate portions of such Fund’s assets and the portfolio
managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Fund’s
assets, the representation set forth above shall solely apply with respect to the portion of assets of the Purchaser managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.

 

(a)               
The Purchaser’s residence (if an individual) or offices in which its investment decision with respect to the Securities
was made (if an entity) are located at the address immediately below the Purchaser’s name on its signature page hereto.

 

(b)              
The Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Common
Stock and other activities with respect to the Common Stock by the Purchasers, and agrees to comply with such rules.

 

		C.	Representations and Warranties of the Company

 

    Except as set forth in
the schedules delivered concurrently with the execution and delivery of this Agreement (the “Disclosure Schedule”),
which Disclosure Schedule shall be deemed a part hereof and shall qualify the representations and warranties of the Company set
forth herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedule, the Company hereby
makes the following representations and warranties to the Purchasers, which representations and warranties shall survive the Closing
and the purchase and sale of the Securities.

 

(1)              
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware and has full corporate power and authority to conduct its business as
currently conducted. The Company is duly qualified to do business as a foreign corporation and is in good standing in all jurisdictions
in which the character of the property owned or leased or the nature of the business transacted by it makes qualification necessary,
except where the failure to be so qualified would not have or reasonably be expected to result in a Material Adverse Effect. For
purposes of this Agreement, “Material Adverse Effect” means a material adverse effect on the results
of operations, assets, prospects, business or financial condition of the Company and its subsidiaries, taken as a whole, except
that any of the following, either alone or in combination, shall not be deemed a Material Adverse Effect: (i) effects caused by
changes or circumstances affecting general market conditions in the U.S. economy or which are generally applicable to the industry
in which the Company operates, provided that such effects are not borne disproportionately by the Company; (ii) effects caused
by earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of
any such hostilities, acts of war, sabotage or terrorism or military actions existing as of the date hereof; (ii) effects resulting
from or relating to the announcement or disclosure of the sale of Securities or other transactions contemplated by this Agreement;
or (iv) effects caused by any event, occurrence or condition resulting directly from or directly relating to the taking of any
action as required in accordance with this Agreement.

 

    	7

    	 

    

 

(2)              
Capitalization. The authorized capital stock of the Company consists of 165,000,000 shares of stock of all classes.
The authorized capital stock is divided into 150,000,000 shares of Common Stock, $0.01 par value per share, and 15,000,000 shares
of Preferred Stock, $0.01 par value per share (the “Preferred Stock”). As of the date hereof, there were 7,353,695
shares of Common Stock issued and 4,029,502 shares of Preferred Stock issued and outstanding. As of the date hereof, the Company
had reserved 1,666,667 shares of Common Stock for issuance to employees, directors and consultants pursuant to the Company’s
2006 Equity Incentive Plan, of which 885,956 shares of Common Stock are subject to outstanding, unexercised options or stock appreciation
rights as of such date. Other than as set forth above, as set forth in footnote 8 to the financial statements of the Company included
in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2014 or as contemplated to be sold pursuant
to this Agreement, there are no other options, warrants, calls, rights, commitments or agreements of any character to which the
Company is a party or by which either the Company is bound or obligating the Company to issue, deliver, sell, repurchase or redeem,
or cause to be issued, delivered, sold, repurchased or redeemed, any shares of the capital stock of the Company or obligating the
Company to grant, extend or enter into any such option, warrant, call, right, commitment or agreement.

 

(3)              
Issuance; Reservation of Shares. The issuance of the Shares has been duly and validly authorized by all necessary
corporate and stockholder action, and the Shares, when issued and paid for pursuant to this Agreement, will be validly issued,
fully paid and non-assessable shares of Common Stock of the Company. The issuance of the Warrants has been duly and validly authorized
by all necessary corporate and stockholder action, and the Warrant Shares, when issued upon the due exercise of the Warrants, will
be validly issued, fully paid and non-assessable shares of Common Stock of the Company. The Company has reserved, and will reserve
at all times that the Warrants remain outstanding, such number of shares of Common Stock sufficient to enable the full exercise
of the Warrants.

 

(4)              
Authorization; Enforceability. The Company has all corporate right, power and authority to enter into this Agreement
and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders
necessary for the authorization, execution, delivery and performance of this Agreement by the Company, the authorization, sale,
issuance and delivery of the Securities contemplated herein and the performance of the Company’s obligations hereunder has
been taken. This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms and subject to laws of general application relating
to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other
equitable remedies, and to limitations of public policy. The issuance and sale of the Securities contemplated hereby will not give
rise to any preemptive rights or rights of first refusal on behalf of any person.

 

    	8

    	 

    

 

(5)              
No Conflict; Governmental and Other Consents.

 

(a)               
The execution and delivery by the Company of this Agreement and the consummation of the transactions contemplated hereby
will not result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court
or governmental authority to or by which the Company is bound, or of any provision of the Amended and Restated Certificate of Incorporation
or Amended and Restated Bylaws of the Company, and will not conflict with, or result in a breach or violation of, any of the terms
or provisions of, or constitute (with due notice or lapse of time or both) a default under, any Material Agreement (as defined
below), nor result in the creation or imposition of any lien upon any of the properties or assets of the Company. 

 

(b)              
No consent, approval, authorization or other order of any governmental authority or other third party is required to be
obtained by the Company in connection with the authorization, execution and delivery of this Agreement or with the authorization,
issue and sale of the Securities, except such post-Closing filings as may be required to be made with the SEC, The NASDAQ
Stock Market LLC (“NASDAQ”) and any state or foreign blue sky or securities
regulatory authority. 

 

(6)              
Litigation. There are no pending, or to the Company’s knowledge threatened, legal or governmental proceedings
against the Company that would, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be
expected to result in a Material Adverse Effect.

 

(7)              
Accuracy of Reports. All reports required to be filed by the Company within the twelve months prior to the date of
this Agreement (the “SEC Reports”) under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), have been filed with the SEC, except where the failure to file on a timely basis would not have or reasonably
be expected to result in a Material Adverse Effect and would not have or reasonably be expected to result in any limitation or
prohibition on the Company’s ability to register the Shares and Warrant Shares for resale on Form S-3 if the Company is eligible
to use Form S-3 for a secondary offering, and, otherwise, on Form S-1, or any Purchaser’s ability to use Rule 144 to resell
any Securities. The SEC Reports complied at the time of filing in all material respects with the requirements of their respective
forms and were complete and correct in all material respects as of the dates at which the information was furnished, and contained
(as of such dates) no untrue statements of a material fact nor omitted to state any material fact necessary in order to make the
statements contained therein, in light of the circumstances under which they were made, not misleading.

 

(8)              
Financial Information. The Company’s financial statements that appear in the SEC Reports have been prepared
in accordance with United States generally accepted accounting principles (“GAAP”), except in the case of unaudited
statements as permitted by Form 10-Q of the SEC or as may be indicated therein or in the notes thereto, applied on a consistent
basis throughout the periods indicated, and such financial statements fairly present in all material respects the financial condition
and results of operations of the Company as of the dates and for the periods indicated therein.

 

    	9

    	 

    

 

(9)              
Accounting Controls. The Company and each of its subsidiaries maintains a system of internal accounting controls
sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management’s general or
specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s
general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.

 

(10)          
Sarbanes-Oxley Act of 2002. The Company is in compliance, in all material respects, with all applicable provisions
of the Sarbanes-Oxley Act of 2002 and all rules and regulations of the SEC or other governmental, regulatory (including self-regulatory)
or similar agency or organization, promulgated thereunder or implementing the provisions thereof that are in effect.

 

(11)          
Absence of Certain Changes. Since the date of the Company’s financial statements included in the Company’s
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2014, there have been no events, occurrences or developments
that have had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, except
in each case as expressly described in the SEC Reports.

 

(12)          
Investment Company. The Company is not an “investment company” within the meaning of such term under
the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

(13)          
Subsidiaries. To the extent required under applicable SEC rules, Exhibit 12.1 to the 2013 Form 10-K sets forth each
subsidiary of the Company, showing the jurisdiction of its incorporation or organization. For the purposes of this Agreement, “subsidiary”
shall mean any company or other entity of which at least 50% of the securities or other ownership interest having ordinary voting
power for the election of directors or other persons performing similar functions are at the time owned directly or indirectly
by the Company or any of its other subsidiaries.

 

(14)          
Certain Fees. Except for the issuance of Warrants to purchase up to 37,500 shares of Common Stock to one or more
“finders” in connection with the Offering as contemplated in Section A(1), no o brokers’, finders’ or financial
advisory fees or commissions will be payable by the Company or any subsidiary with respect to the transactions contemplated by
this Agreement.

 

(15)          
Material Agreements. Except as set forth in the SEC Reports, neither the Company nor any subsidiary is a party to
any written or oral contract, instrument, agreement, commitment, obligation, plan or arrangement, a copy of which would be required
to be filed with the SEC as an exhibit to Form 10-K (each, a “Material Agreement”). The Company and each of
its subsidiaries has in all material respects performed all the obligations required to be performed by them to date under the
foregoing agreements, have received no notice of default by the Company or the subsidiary that is a party thereto, as the case
may be, and, to the Company’s knowledge, are not in default under any Material Agreement now in effect.

 

    	10

    	 

    

 

(16)          
Transactions with Affiliates. Except as set forth in the SEC Reports, none of the executive officers or directors
of the Company and, to the Company’s knowledge, none of the employees of the Company, is presently a party to any transaction
with the Company (other than for services as employees, officers and directors) that would be required to be disclosed pursuant
to Item 404 of Regulation S-K promulgated under the Securities Act.

 

(17)          
Taxes. The Company and each of the subsidiaries has prepared and filed (or requested valid extensions thereof) all
federal, state, local, foreign and other tax returns for income, gross receipts, sales, use and other taxes and custom duties (“Taxes”)
required by law to be filed by it. The Company and each subsidiary has paid or made provisions for the payment of all Taxes shown
to be due on such tax returns and all additional assessments, and adequate provisions have been and are reflected in the financial
statements of the Company and the subsidiaries for all current Taxes to which the Company or any subsidiary is subject and which
are not currently due and payable except where the failure to so pay or make provision for any such Taxes would not have or reasonably
be expected to result in a Material Adverse Effect. There are no unpaid taxes in any material amount claimed to be due by the Company
or any Subsidiary by the taxing authority of any jurisdiction.

 

(18)          
Insurance. The Company and its subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as the Company believes are prudent and customary in the businesses in which the Company
and its subsidiaries are engaged. Neither the Company nor any of its subsidiaries has any reason to believe that it will not be
able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business without an increase in cost significantly greater than general increases in cost experienced
for similar companies in similar industries with respect to similar coverage.

 

(19)          
Environmental Matters. Except as disclosed in the SEC Reports, to the Company’s knowledge, all real property
owned, leased or otherwise operated by the Company and its subsidiaries is free of contamination from any substance, waste or material
currently identified to be toxic or hazardous pursuant to, within the definition of a substance which is toxic or hazardous under,
or which may result in liability under, any Environmental Law (as defined below), including, without limitation, any asbestos,
polychlorinated biphenyls, radioactive substance, methane, volatile hydrocarbons, industrial solvents, oil or petroleum or chemical
liquids or solids, liquid or gaseous products, or any other material or substance (“Hazardous Substance”) which
has caused or would reasonably be expected to cause or constitute a threat to human health or safety, or an environmental hazard
in violation of Environmental Law or to result in any environmental liabilities. Neither the Company nor any of its subsidiaries
has caused or suffered to occur any release, spill, migration, leakage, discharge, disposal, uncontrolled loss, seepage, or filtration
of Hazardous Substances that would reasonably be expected to result in a Material Adverse Effect. The Company and each subsidiary
has generated, treated, stored and disposed of any Hazardous Substances in compliance with applicable Environmental Laws. There
are no investigations, proceedings or litigation pending or, to the Company's knowledge, threatened against the Company, any of
its subsidiaries or any of the Company’s or its subsidiaries’ facilities relating to Environmental Laws or Hazardous
Substances. “Environmental Laws” shall mean all federal, national, state, regional and local laws, statutes,
ordinances and regulations, in each case as amended or supplemented from time to time, and any judicial or administrative interpretation
thereof, including orders, consent decrees or judgments relating to the regulation and protection of human health, safety, the
environment and natural resources.

 

    	11

    	 

    

 

(20)          
Intellectual Property Rights and Licenses. The Company and its subsidiaries own or have the right to use any and
all information, know-how, trade secrets, patents, copyrights, trademarks, trade names, software, formulae, methods, processes
and other intangible properties that are of a such nature and significance to the business that the failure to own or have the
right to use such items would be reasonably likely to have a Material Adverse Effect (“Intangible Rights”).
The Company (including its subsidiaries) has not received any notice that it is in conflict with or infringing upon the asserted
intellectual property rights of others in connection with the Intangible Rights, and, to the Company’s knowledge, neither
the use of the Intangible Rights nor the operation of the Company’s businesses is infringing or has infringed upon any intellectual
property rights of others. All payments have been duly made that are necessary to maintain the Intangible Rights in force. No claims
have been made, and to the Company’s knowledge, no claims are threatened, that challenge the validity or scope of any Intangible
Right of the Company or any of its subsidiaries.

 

(21)          
Labor, Employment and Benefit Matters.

 

(a)               
There are no existing, or to the best of the Company’s knowledge, threatened strikes or other labor disputes against
the Company or any of its subsidiaries.  Except as set forth in the SEC Reports, there is
no organizing activity involving employees of the Company or any of its subsidiaries pending or, to the Company’s or its
subsidiaries’ knowledge, threatened by any labor union or group of employees.  There
are no representation proceedings pending or, to the Company’s or its subsidiaries’ knowledge, threatened with the
National Labor Relations Board, and no labor organization or group of employees of the Company or its subsidiaries has made a pending
demand for recognition. 

 

(b)              
Except as set forth in the SEC Reports, neither the Company nor any of its subsidiaries is, or during the five years preceding
the date of this Agreement was, a party to any labor or collective bargaining agreement and there are no labor or collective bargaining
agreements which pertain to employees of the Company or its subsidiaries.

 

(c)               
Each employee benefit plan is in compliance in all material respects with all applicable law.

 

(22)          
Compliance with Law. The Company is in compliance in all material respects with all applicable laws. The Company
has not received any notice of, nor does the Company have any knowledge of, any material violation (or of any investigation, inspection,
audit or other proceeding by any governmental entity involving allegations of any violation) of any applicable law involving or
related to the Company which has not been dismissed or otherwise disposed of. The Company has not received written notice or otherwise
has any knowledge that the Company is charged with, threatened with or under investigation with respect to, any material violation
of any applicable law. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any employee or agent
of the Company or any subsidiary has made any contribution or other payment to any official of, or candidate for, any federal,
state or foreign office in violation of any law. The Company and, to the Company’s knowledge, its directors, officers, employees
and agents have complied in all material respects with the Foreign Corrupt Practices Act of 1977, as amended, and any related rules
and regulations.

 

    	12

    	 

    

 

(23)          
Ownership of Property. Except as set forth in the Company’s financial statements included in the SEC Reports,
each of the Company and its subsidiaries has (i) good and marketable fee simple title to its owned real property, if any, free
and clear of all liens; (ii) a valid leasehold interest in all leased real property, and each of such leases is valid and enforceable
in accordance with its terms (subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors
and rules of law governing specific performance, injunctive relief or other equitable remedies, and to limitations of public policy)
and is in full force and effect, and (iii) good title to, or valid leasehold interests in, all of its other properties and assets
free and clear of all liens.

 

(24)          
Compliance with NASDAQ Listing Requirements. The Company is in compliance in all material respects with all currently
effective NASDAQ continued listing requirements and corporate governance requirements.

 

(25)          
No Integrated Offering. Assuming the accuracy of each Purchaser’s representations and warranties set forth
in Section B hereof, neither the Company, nor to the Company’s knowledge, any of its affiliates or other person acting on
the Company’s behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy
any security under circumstances that would cause the Offering of the Securities to be integrated with prior offerings by the Company
for purposes of the Securities Act, when integration would cause the Offering not to be exempt from the requirements of Section
5 of the Securities Act.

 

(26)          
General Solicitation. Neither the Company nor, to its knowledge, any person acting on behalf of the Company, has
offered or sold any of the Securities by any form of “general solicitation” within the meaning of Rule 502 under the
Securities Act. To the knowledge of the Company, no person acting on its behalf has offered the Securities for sale other than
to the Purchasers and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.

 

		D.	Understandings

 

    Each of the Purchasers understands, acknowledges
and agrees with the Company as follows:

 

    	13

    	 

    

 

(1)              
The Company may terminate this Offering or reject any subscription at any time in its sole discretion. The execution of
this Agreement by the Purchaser or solicitation of the investment contemplated hereby shall create no obligation on the part of
the Company to accept any subscription or complete the Offering.

 

(2)              
The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser, and that,
except as required by law, the Purchaser is not entitled to cancel, terminate or revoke this Agreement or any agreements of the
Purchaser hereunder and that if the Purchaser is an individual this Agreement shall survive the death or disability of the Purchaser
and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal
representatives and permitted assigns.

 

(3)              
No federal or state agency or authority has made any finding or determination as to the accuracy or adequacy of the Offering
Documents or as to the fairness of the terms of the Offering nor any recommendation or endorsement of the Securities. Any representation
to the contrary is a criminal offense. In making an investment decision, Purchasers must rely on their own examination of the Company
and the terms of the Offering, including the merits and risks involved.

 

(4)              
The Offering is intended to be exempt from registration under the Securities Act by virtue of Section 4(2) of the Securities
Act and the provisions of Regulation D thereunder, which is in part dependent upon the truth, completeness and accuracy of the
statements made by the Purchaser herein and in the Purchaser Questionnaire.

 

(5)              
Notwithstanding the registration obligations provided herein, there can be no assurance that the Purchaser will be able
to sell or dispose of the Securities. It is understood that in order not to jeopardize the Offering’s exempt status under
Section 4(2) of the Securities Act and Regulation D, any transferee may, at a minimum, be required to fulfill the investor suitability
requirements thereunder.

 

(6)              
The Purchaser acknowledges that the Offering is confidential and non-public and agrees that all information about the Offering
(including the existence and terms of this Agreement) shall be kept in confidence by the Purchaser until the public announcement
of the Offering by the Company.

 

(7)              
The Purchaser acknowledges that the foregoing restrictions on the Purchaser’s use and disclosure of any such confidential,
non-public information contained in the above-described documents restricts the Purchaser from trading in the Company’s securities
to the extent such trading is on the basis of material, non-public information of which the Purchaser is aware. Except for the
terms of the transaction documents and the fact that the Company is considering consummating the transactions contemplated therein,
the Company confirms that neither the Company nor, to its knowledge, any other person acting on its behalf, has provided any of
the Purchasers or their agents or counsel with any information that constitutes material, non-public information.

 

(8)              
The Purchaser agrees that beginning on the date hereof until the Offering is publicly announced by the Company (which will
occur as soon as practicable following the Company’s acceptance of the subscriptions for Securities in connection with this
Agreement), the Purchaser will not enter into any Short Sales.

 

    	14

    	 

    

 

		E.	Registration Rights

 

(1)              
Certain Definitions. For purposes of this Section E, the following terms shall have the meanings ascribed to them
below.

 

(a)               
“Prospectus” means the prospectus included in the Registration Statement (including, without limitation,
a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement
in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with
respect to the terms of the Offering of any portion of the Registrable Securities covered by the Registration Statement, and all
other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference
or deemed to be incorporated by reference in such Prospectus.

 

(b)              
“Registrable Securities” shall mean any Shares and Warrant Shares issued or issuable pursuant to the
Offering Documents together with any securities issued or issuable upon any stock split, dividend or other distribution, adjustment,
recapitalization or similar event with respect to the foregoing; provided that, with respect to a particular Purchaser (or
transferee thereof), such Purchaser’s Shares, Warrant Shares and other securities of the Company shall cease to be Registrable
Securities upon the earliest to occur of the following: (i) a sale pursuant to a Registration Statement or Rule 144 under the Securities
Act (in which case, only such security sold by the Purchaser (or transferee thereof) shall cease to be a Registrable Security);
or (ii) such securities first becoming eligible for resale by the Purchaser (or transferee thereof) under Rule 144 without the
requirement for the Company to be in compliance with the current public information requirement thereunder and without volume or
manner-of-sale restrictions.

 

(c)               
“Registration Statement” means the registration statement required to be filed under this Section E,
including the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such
registration statement.

 

(2)              
Registration Statement.

 

(a)               
The Company shall use its best efforts to cause to prepare and file with the SEC a Registration Statement covering the resale
of all Registrable Securities for an offering to be made on a continuous basis pursuant to Rule 415 on or prior to the 30th day
following the Closing date (such date of actual filing, the “Filing Date”). 
The Registration Statement shall be on Form S-3, if the Company is eligible to use Form S-3 for a secondary offering, and, otherwise,
on Form S-1, and shall contain (except if otherwise directed by the Purchasers) a “Plan of Distribution” substantially
in the form attached hereto as Exhibit E.  Each Purchaser will furnish to the Company
in writing the information specified in Item 507 or 508 of Regulation S-K, as applicable, of the Securities Act for use in connection
with the Registration Statement or prospectus or preliminary prospectus included therein. 
Each Purchaser agrees to promptly furnish additional information required to be disclosed in order to make the information previously
furnished to the Company by such Purchaser not materially misleading.  The Registration
Statement shall register the Registrable Securities for resale by the holders thereof.

 

    	15

    	 

    

 

(b)              
The Company shall use its best efforts to cause the Registration Statement to be declared effective by the SEC on or prior
to the 90th day following the Closing date, and shall use its best efforts to keep the Registration Statement continuously effective
under the Securities Act until the earliest of (i) the first anniversary of the Closing date or (ii) the date when all Registrable
Securities covered by such Registration Statement have been sold (the “Effectiveness Period”).

 

(c)               
The Company shall notify each Purchaser in writing promptly (and in any event within one business day) after receiving notification
from the SEC that the Registration Statement has been declared effective.

 

(d)              
Upon the occurrence of any Event (as defined below), as partial relief for the damages suffered therefrom by the Purchasers
(which remedy shall not be exclusive of any other remedies which are available at law or in equity; and provided further that the
Purchasers shall be entitled to pursue an action for specific performance of the Company’s obligations under Paragraph (2)(b)
above and any such actions at law, in equity, for specific performance or otherwise shall not require the Purchaser to post a bond),
the Company shall pay to each Purchaser, as liquidated damages and not as a penalty (it being agreed that it would not be feasible
to ascertain the extent of such damages with precision), such amounts and at such times as shall be determined pursuant to this
Paragraph (2)(d).  For such purposes, each of the following shall constitute an “Event”:

 

(i)                
the Filing Date does not occur on or prior to the later of the 30th day following the Closing date, in which case the Company
shall pay (A) on the 31st day following the Closing date an amount in cash equal to one and one-half percent (1.5%) of the aggregate
purchase price paid by such Purchaser; and (B) on the calendar day following every successive 30-day period thereafter or any portion
thereof until the Filing Date, one percent (1.0%) of the aggregate purchase price paid by such Purchaser; or

 

(ii)              
the Registration Statement is not declared effective on or prior to the date that is 90 days after the Closing date (the
“Required Effectiveness Date”), in which case the Company shall pay (A) on the calendar day following the Required
Effectiveness Date an amount in cash equal to one and one-half percent (1.5%) of the aggregate purchase price paid by such Purchaser
and (B) on the calendar day following every successive 30-day period thereafter during which the Required Effectiveness Date has
not occurred an amount in cash equal to one percent (1.0%) of the aggregate purchase price paid by such Purchaser.

 

The payment obligations
of the Company under this Paragraph (2)(d) shall be cumulative.

 

    	16

    	 

    

 

(3)              
Registration Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:

 

(a)               
(i) prepare and file with the SEC such amendments, including post-effective amendments, to the Registration Statement as
may be necessary to keep the Registration Statement continuously effective as to the Registrable Securities for the Effectiveness
Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented
or amended to be filed pursuant to Rule 424; and (iii) respond as promptly as reasonably possible to any comments received from
the SEC with respect to the Registration Statement or any amendment thereto and as promptly as reasonably possible provide true
and complete copies of all correspondence from and to the SEC relating to the Registration Statement that pertains to the holders
of Registrable Securities as “Selling Stockholders” but not any comments that would result in the disclosure to such
holders of material and non-public information concerning the Company.

 

(b)              
Notify the Purchasers as promptly as reasonably possible, and (if requested by the Purchasers) confirm such notice in writing
no later than one (1) trading day thereafter, of any of the following events:  (i) the SEC
notifies the Company whether there will be a “review” of the Registration Statement; (ii) the SEC comments in writing
on the Registration Statement (in which case the Company shall deliver to the holders of Registrable Securities a copy of such
comments that pertain to such holders as “Selling Stockholders” or to the “Plan of Distribution” and all
written responses thereto, but not information that the Company believes would constitute material and non-public information);
(iii) the SEC or any other Federal or state governmental authority in writing requests any amendment or supplement to the Registration
Statement or Prospectus or requests additional information related thereto; (iv) if the SEC issues any stop order suspending the
effectiveness of the Registration Statement or initiates any action, claim, suit, investigation or proceeding (a “Proceeding”)
for that purpose; (v) the Company receives notice in writing of any suspension of the qualification or exemption from qualification
of any Registrable Securities for sale in any jurisdiction, or the initiation or threat of any Proceeding for such purpose; or
(vi) the financial statements included in the Registration Statement become ineligible for inclusion therein or any statement made
in the Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference is untrue
in any material respect or any revision to the Registration Statement, Prospectus or other document is required so that it will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(c)               
Use its reasonable best efforts to avoid the issuance of or, if issued, obtain the withdrawal of (i) any order suspending
the effectiveness of the Registration Statement or (ii) any suspension of the qualification (or exemption from qualification) of
any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

(d)              
If requested by a Purchaser, promptly deliver to such Purchaser, without charge, such reasonable number of copies of the
Prospectus or Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such Purchasers may
reasonably request.  The Company hereby consents to the use of such Prospectus and each
amendment or supplement thereto by each of the selling Purchasers in connection with the offering and sale of the Registrable Securities
covered by such Prospectus and any amendment or supplement thereto.

 

    	17

    	 

    

 

(e)               
(i)  In the time and manner required by NASDAQ, prepare and file with NASDAQ an additional
shares listing application covering all of the Registrable Securities and a notification form regarding the change in the number
of the Company’s outstanding Shares; (ii) use its reasonable best efforts, regardless of listing or similar costs, to take
all steps necessary to cause such Registrable Securities to be approved for listing on NASDAQ as soon as possible thereafter; (iii)
provide to the Purchasers notice of such listing; and (iv) use its reasonable best efforts, regardless of listing or similar costs,
to maintain the listing of such Registrable Securities on NASDAQ.

 

(f)               
Prior to any resale of Registrable Securities by a Purchaser, use its commercially reasonable efforts to register or qualify
or cooperate with the selling Purchasers in connection with the registration or qualification (or exemption from such registration
or qualification) of such Registrable Securities for offer and sale under the securities or “blue sky” laws of such
jurisdictions within the United States as any Purchaser requests in writing, to keep each such registration or qualification (or
exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things necessary or advisable
to enable the disposition in such jurisdictions of the Registrable Securities covered by a Registration Statement; provided, however,
that the Company shall not be required for any such purpose to (i) qualify generally to do business as a foreign corporation in
any jurisdiction wherein it would not be otherwise required to qualify but for the requirements of this Paragraph (3)(f), (ii)
subject itself to taxation; or (iii) file a general consent to service of process in any such jurisdiction.

 

(g)              
Upon the occurrence of any event described in Paragraph (3)(b)(vi) above, as promptly as reasonably possible, prepare a
supplement or amendment, including a post-effective amendment, to the affected Registration Statement or a supplement to the related
Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document
so that, as thereafter delivered, neither the Registration Statement nor such Prospectus will contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading; provided, however, that the Company may suspend
sales pursuant to the Registration Statement for a period of up to sixty (60) days (unless the holders of at least two-thirds of
the Registrable Securities consent in writing to a longer delay of up to an additional thirty (30) days) no more than once in any
twelve-month period if the Company furnishes to the holders of the Registrable Securities a certificate signed by the Company’s
Chief Executive Officer stating that in the good faith judgment of the Company’s Board of Directors, (i) the offering could
reasonably be expected to interfere in any material respect with any acquisition, corporate reorganization or other material transaction
under consideration by the Company or (ii) there is some other material development relating to the operations or condition (financial
or other) of the Company that has not been disclosed to the general public and as to which it is in the Company’s best interests
not to disclose such development; provided further, however, that the Company may not so suspend sales more than once in
any calendar year without the written consent of the holders of at least two-thirds of the Registrable Securities.

 

    	18

    	 

    

 

(h)              
Comply with all applicable rules and regulations of the SEC and NASDAQ in all material respects.

 

(4)              
Registration Expenses. The Company shall pay (or reimburse the Purchasers for) all fees and expenses incident to
the performance of or compliance with this Agreement by the Company, including without limitation (a) all registration and filing
fees and expenses, including without limitation those related to filings with the SEC, NASDAQ and in connection with applicable
state securities or “Blue Sky” laws, (b) printing expenses (including, without limitation, expenses of printing certificates
for Registrable Securities and of printing copies of Prospectuses reasonably requested by the Purchasers), (c) messenger, telephone
and delivery expenses, (d) fees and disbursements of counsel for the Company and fees and disbursements, up to an aggregate of
$15,000, of a single counsel for all the Purchasers, and (e) fees and expenses of all other Persons retained by the Company in
connection with the consummation of the transactions contemplated by this Agreement. Notwithstanding the foregoing, each Purchaser
shall pay any and all costs, fees, discounts or commissions attributable to the sale of its respective Registrable Securities.

 

(5)              
Indemnification.

 

(a)               
Indemnification by the Company.  The Company shall, notwithstanding any termination
of this Agreement, indemnify and hold harmless each Purchaser, its officers and directors, partners, members, agents, brokers and
employees of each of them, each Person who controls any such Purchaser (within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act) and the officers, directors, partners, members, agents and employees of each such controlling
Person, and each underwriter of Registrable Securities, to the fullest extent permitted by applicable law, from and against any
and all losses, claims, damages, liabilities, settlement costs and expenses, including without limitation reasonable costs of preparation
and reasonable attorneys’ fees (collectively, “Losses”), as incurred, arising out of or are based on any
untrue or alleged untrue statement of a material fact contained in the Registration Statement, any Prospectus or form of prospectus
or in any amendment or supplement thereto (it being understood that the Purchasers have approved Exhibit E attached hereto for
this purpose), or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein
or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in light
of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that (i) such untrue
statements, alleged untrue statements or omissions are based upon information regarding such Purchaser furnished in writing to
the Company by such Purchaser, or to the extent that such information related to such Purchaser or such Purchaser’s proposed
method of distribution of Registrable Securities and was reviewed and approved in writing by such Purchaser expressly for use in
the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto ( it being understood
that the Purchasers have approved Exhibit E attached hereto for this purpose), or (ii) in the case of an occurrence of an event
of the type specified in Paragraph (3)(b) above, the use by such Purchaser of an outdated or defective Prospectus after the Company
has notified such Purchaser in writing that the Prospectus is outdated or defective and prior to the receipt by such Purchaser
of the Advice contemplated in Paragraph (6) below.  The Company shall notify the Purchasers
promptly of the institution, threat or assertion of any Proceeding of which the Company is aware in connection with the transactions
contemplated by this Agreement.

 

    	19

    	 

    

 

(b)              
Indemnification by Purchasers.  Each Purchaser shall, severally and not jointly,
indemnify and hold harmless the Company, its directors, officers, agents, stockholders and employees, and each Person who controls
the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses,
as incurred, arising out of or based upon (i) such Purchaser’s failure to comply with the prospectus delivery requirements
of the Securities Act, (ii)any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement,
any Prospectus, or any form of prospectus or in any amendment or supplement thereto, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein (in the case of any Prospectus or form of prospectus or supplement
thereto, in light of the circumstances under which they were made) or necessary to make the statements therein not misleading to
the extent, but only to the extent, that such untrue statement, alleged untrue statement or omission is contained in any information
furnished in writing by such Purchaser to the Company specifically for inclusion in such Registration Statement or Prospectus or
to the extent that (i) such untrue statements, alleged untrue statements or omissions are based upon information regarding such
Purchaser furnished in writing to the Company by such Purchaser for use therein, or to the extent that such information related
to such Purchaser or such Purchaser’s proposed method of distribution of Registrable Securities and was reviewed and approved
in writing by such Purchaser expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in
any amendment or supplement thereto ( it being understood that the Purchasers have approved Exhibit E attached hereto for this
purpose), or (ii) in the case of an occurrence of an event of the type specified in Paragraph (3)(b) above, the use by such Purchaser
of an outdated or defective Prospectus after the Company has notified such Purchaser in writing that the Prospectus is outdated
or defective and prior to the receipt by such Purchaser of the Advice contemplated in Paragraph (6) below. 
In no event shall the liability of any selling Purchaser hereunder be greater in amount than the dollar amount of the net proceeds
received by such Purchaser upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

    	20

    	 

    

 

(c)               
Conduct of Indemnification Proceedings.  If any Proceeding shall be brought
or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party
shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the
Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory
to the Indemnified Party and the payment of all reasonable fees and expenses incurred in connection with defense thereof, provided,
that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities
pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction
(which determination is not subject to appeal or further review) that such failure shall have prejudiced the Indemnifying Party.
 An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and
to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party
or Parties unless: (i) the Indemnifying Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party
shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified
Party in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both
such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict
of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which
case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense
of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and such counsel shall
be at the expense of the Indemnifying Party; provided, however, that in the event that the Indemnifying Party shall be required
to pay the fees and expenses of separate counsel, the Indemnifying Party shall only be required to pay the fees and expenses of
one separate counsel for such Indemnified Party or Parties.  The Indemnifying Party shall
not be liable for any settlement of any such Proceeding affected without its prior written consent, which consent shall not be
unreasonably withheld, conditioned or delayed.  No Indemnifying Party shall, without the
prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified
Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such Proceeding.  All fees and expenses of the Indemnified
Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such
Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within 20 trading
days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that an Indemnified
Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to
undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party
is not entitled to indemnification hereunder). The failure to deliver written notice to the Indemnifying Party within a reasonable
time of the commencement of any such action shall not relieve such Indemnifying Party of any liability to the Indemnified Party
under this Section (5), except to the extent that the Indemnifying Party is materially and adversely prejudiced in its ability
to defend such action.

 

    	21

    	 

    

 

(d)              
Contribution.  If a claim for indemnification under Paragraph (5)(a) or (b)
is unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying
such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in
such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with
the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations.
 The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference
to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or
omission or alleged omission of a material fact, has been taken or made by, or related to information supplied by, such Indemnifying
Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such action, statement or omission.  The amount paid or payable by a party as
a result of any Losses shall be deemed to include, subject to the limitations set forth in Paragraph (5)(c), any reasonable attorneys’
or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have
been indemnified for such fees or expenses if the indemnification provided for in this Paragraph 5(d) was available to such party
in accordance with its terms.

 

The parties hereto
agree that it would not be just and equitable if contribution pursuant to this Paragraph (5)(d) were determined by pro rata allocation
or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. Notwithstanding the provision of this Paragraph (5)(d), no Purchaser shall be required to contribute, in the
aggregate, any amount in excess of the amount by which the proceeds actually received by such Purchaser from the sale of the Registrable
Securities subject to the Proceeding exceeds the amount of any damages that such Purchaser has otherwise been required to pay by
reason of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation.

 

The indemnity and contribution
agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified
Parties.

 

    	22

    	 

    

 

(6)              
Dispositions. Each Purchaser agrees that it will comply with the prospectus delivery requirements of the Securities
Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement. Each Purchaser
further agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Paragraphs
(3)(b), such Purchaser will discontinue disposition of such Registrable Securities under the Registration Statement until such
Purchaser’s receipt of the copies of the supplemented Prospectus and/or amended Registration Statement contemplated by Paragraph
(3)(g), or until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus
(as it may have been supplemented or amended) may be resumed, and, in either case, has received copies of any additional or supplemental
filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The Company
may provide appropriate stop orders to enforce the provisions of this paragraph.

 

(7)              
No Piggy-Back on Registrations. Neither the Company nor any of its security holders (other than the Purchasers in
such capacity) may include securities of the Company in the Registration Statement other than the Registrable Securities, and the
Company shall not after the date hereof enter into any agreement providing any such right with respect to the Registration Statement
to any of its security holders.

 

(8)              
Piggy-Back Registrations. If at any time during the Effectiveness Period, other than any suspension period referred
to in Paragraph (3)(g), there is not an effective Registration Statement covering all of the Registrable Securities and the Company
shall determine to prepare and file with the SEC a registration statement relating to an offering for its own account or the account
of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under
the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition
of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the
Company shall send to each Purchaser written notice of such determination and if, within ten days after receipt of such notice,
any such Purchaser shall so request in writing, the Company shall include in such registration statement all or any part of such
Registrable Securities not already covered by an effective Registration Statement such Purchaser requests to be registered.

 

    	23

    	 

    

 

		F.	Conditions Precedent to the Obligations of the Company to Sell Securities

 

The Company’s
obligation to sell and issue the Shares and Warrants at the Closing to the Purchasers is subject to the fulfillment to the satisfaction
of the Company, on or prior to the Closing date, of the following conditions, any of which may be waived by the Company:

 

(1)              
The representations and warranties made by the Company in Section B of this Agreement were true and correct in all material
respects (other than representations and warranties which are already qualified as to materiality, which shall be true and correct
in all respects) when made and are true and correct in all material respects (other than representations and warranties which are
already qualified as to materiality, which shall be true and correct in all respects) on the date of Closing relating to the Securities
subscribed for pursuant to this Agreement as though made on and as of the Closing date (provided, however, that representations
and warranties that speak as of a specific date shall continue to be true and correct as of the Closing with respect to such date).

 

(2)              
No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by this Agreement.

 

(3)              
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers
necessary for consummation of the purchase and sale of the Securities at the Closing, all of which shall be and remain so long
as necessary in full force and effect.

 

(4)              
Each of the Purchasers shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing
date.

 

(5)              
Each of the Purchasers shall have delivered or caused to be delivered to the Company, with respect to such Purchaser, a
Company Purchaser Questionnaire and a Selling Stockholder Questionnaire.

 

		G.	Covenants of the Company

 

(1)              
The Company hereby agrees that until thirty (30) days following effectiveness of the Registration Statement, it shall not
issue or sell any Common Stock of the Company, any warrants or other rights to acquire Common Stock or any other securities that
are convertible into Common Stock, with the exception of issuances or sales pursuant to the Company’s 2006 Equity Incentive
Plan.

 

(2)              
As soon as practicable, and in accordance with applicable rules and regulations, following the Closing, the Company shall,
by filing a Current Report on Form 8-K and/or by issuance of a press release, disclose the Closing of the Offering and any material,
non-public information disclosed to the Purchasers in connection therewith.

 

    	24

    	 

    

 

		H.	Miscellaneous

 

(1)              
All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, singular or plural,
as identity of the person or persons may require. The headings herein are for convenience only, do not constitute a part of this
Agreement and shall not be deemed to limit or affect any of the provisions hereof. Any references to paragraphs, subparagraphs,
sections or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary. The language
used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of
strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties,
and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions
of this Agreement.

 

(2)              
Any notice or other document required or permitted to be given or delivered to the Purchasers shall be in writing and sent
(a) by fax if the sender on the same day sends a confirming copy of such notice by an internationally recognized overnight delivery
service (charges prepaid) or (b) by an internationally recognized overnight delivery service (with charges prepaid):

 

(i)                
if to the Company, at

 

Transgenomic,
Inc.

12325 Emmet Street

Omaha, NE 68164

Fax No.: (402) 452-5401

Attention:
 Chief Executive Officer

 

or such other address as it shall have specified to
the Purchaser in writing, with a copy (which shall not constitute notice) to:

Paul Hastings LLP

1117 S. California Avenue

Palo Alto, CA 94304

Fax: (650) 320-1904

Attention: Jeffrey
T. Hartlin, Esq.

 

(ii)              
if to the Purchaser, at its address set forth on the signature page to this Agreement, or such other address as it shall
have specified to the Company in writing.

 

(3)              
Failure of the Company to exercise any right or remedy under this Agreement or any other agreement between the Company and
the Purchaser, or otherwise, or delay by the Company in exercising such right or remedy, will not operate as a waiver thereof.
No waiver by the Company will be effective unless and until it is in writing and signed by the Company.

 

(4)              
This Agreement shall be enforced, governed and construed in all respects in accordance with the laws of the State of New
York, as such laws are applied by the New York courts to agreements entered into and to be performed in New York by and between
residents of New York, and shall be binding upon the Purchaser, the Purchaser’s heirs, estate, legal representatives, successors
and assigns and shall inure to the benefit of the Company, its successors and assigns.

 

    	25

    	 

    

 

(5)              
If any provision of this Agreement is held to be invalid or unenforceable under any applicable statute or rule of law, then
such provision shall be deemed modified to conform with such statute or rule of law. Any provision hereof that may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provisions hereof.

 

(6)              
The parties understand and agree that, unless provided otherwise herein, money damages would not be a sufficient remedy
for any breach of the Agreement by the Company or the Purchaser and that the party against which such breach is committed shall
be entitled to equitable relief, including injunction and specific performance, as a remedy for any such breach. Such remedies
shall not, unless provided otherwise herein, be deemed to be the exclusive remedies for a breach by either party of the Agreement
but shall be in addition to all other remedies available at law or equity to the party against which such breach is committed.

 

(7)              
The obligations of each Purchaser under this Agreement are several and not joint with the obligations of any other Purchaser,
and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser hereunder, except
as may result from the actions of any such Purchaser other than through the execution hereof. Nothing contained herein solely by
virtue of being contained herein shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture
or any similar entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect
to such obligations or the transactions contemplated hereby.

 

(8)              
This Agreement, together with the agreements and documents executed and delivered in connection with this Agreement, constitutes
the entire agreement between the parties hereto with respect to the subject matter hereof.

 

		I.	Signature

 

The signature page of this Agreement is
contained as part of the applicable subscription package, entitled “Signature Page”.

 

* * * * * * *

 

    	26

    	 

    

 

SIGNATURE PAGE

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	 	THE COMPANY:	 
	 	 	 
	 	TRANSGENOMIC, INC.	 
	 	 	 	 
	 	By:	 	 
	 	Name:	Paul Kinnon	 
	 	Title:	President and CEO	 

 

[SIGNATURE PAGES
OF PURCHASERS FOLLOW]

 

    	[Signature Page to Securities Purchase Agreement]

    	 

    

 

SIGNATURE PAGE

 

The Purchaser hereby
subscribes for such number of Shares as shall equal the Subscription Amount as set forth below, divided by the Offering Price,
and shall also receive a Warrant to purchase such number of shares of Common Stock calculated as set forth in this Agreement, and
agrees to be bound by the terms and conditions of this Agreement.

 

PURCHASER  

 

	 	1.	Dated:
    October        , 2014
	 	 	 
	 	2.	Total Subscription Amount: $____________________
	 	 	 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

______________________________                                                              ______________________________

Signature of Purchaser                                                                                            Signature of Joint Purchaser

                                                                                                                                    (if any)

 

______________________________                                                              ______________________________

Name of Signatory(for
Entities)                                                                            Name of Signatory (for Entities)

 

 

______________________________                                                              ______________________________

Title of Signatory
(for Entities)                                                                              Title of Signatory (for Entities)

 

_____________________________                                                                   ______________________________

Taxpayer Identification or Social                                                                           Taxpayer
Identification or Social

Security Number                                                                                                       Security
Number of Joint Purchaser (if any)

 

Number and Street:
                                                                                                                

 

City, State and
Zip Code:                                                                                                                 

Delivery Instructions for Stock Certificates and Warrants (if different than address above):

 

c/o: _______________________________

 

Number and Street:
____________________________

 

City, State and Zip
Code : _____________________

 

Attention:_________________________

 

    	[Signature Page to Securities Purchase Agreement]Exhibit 4.2

 

NEITHER THESE SECURITIES
NOR THE SECURITIES ISSUABLE UPON EXERCISE 27OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

TRANSGENOMIC, INC.

WARRANT TO PURCHASE COMMON STOCK

 

Original Issue Date: October 22, 2014

 

Transgenomic, Inc.,
a Delaware corporation (the “Company”), hereby certifies that, for value received, ______________ or
its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to a total
of __________ shares of common stock, $0.01 par value per share (the “Common Stock”), of the Company
(each such share, a “Warrant Share” and all such shares, the “Warrant Shares”)
at an exercise price per share equal to $4.00 per share (as adjusted from time to time as provided in Section 9 herein,
the “Exercise Price”), at any time and from time to time beginning on the date that is six months from
the date hereof  (the “Original Exercise Date”) and through and including 5:30 p.m., New York
City time, on April 22, 2020 (the “Expiration Date”), and subject to the following terms and conditions:

 

This Warrant (this
“Warrant”) is one of a series of similar warrants issued pursuant to that certain Securities Purchase
Agreement, dated October 22, 2014, by and among the Company and the Purchasers identified therein (the “Purchase Agreement”).
All such warrants are referred to herein, collectively, as the “Warrants.”

 

1.                 
Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise
defined herein have the meanings given to such terms in the Purchase Agreement.

 

2.                 
Registration of Warrants. The Company shall register this Warrant, upon records to be maintained by the Company for
that purpose, which may be a third-party transfer agent (the “Warrant Register”), in the name of the
record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is
permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.

 

    	1

    	 

    

 

3.                 
Registration of Transfers. Subject to the restrictions on transfer set forth in Section 4.1 of the Purchase
Agreement and compliance with all applicable securities laws, the Company shall register the transfer of all or any portion of
this Warrant in the Warrant Register, upon surrender of this Warrant, with an assignment, in the form attached as Schedule 2
hereto, duly completed and signed, to the Company’s transfer agent or to the Company at its address specified in the Purchase
Agreement and (a) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company to the
effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration requirements
of the Securities Act and all applicable state securities or blue sky laws (other than in connection with any transfer (i) pursuant
to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144 (provided that such Holder provides the
Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the securities
may be sold pursuant to such rule) or (iv) in connection with a bona fide pledge), and (b) delivery by the transferee of a written
statement to the Company certifying that the transferee is an “accredited investor” as defined in Rule 501(a) under
the Securities Act and making the representations and certifications set forth in Sections B(6), (7), (11), (12), (14) and (16)
of the Purchase Agreement, to the Company at its address specified in the Purchase Agreement. Upon any such registration or transfer,
a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”)
evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining
portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant
by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of
the New Warrant that the Holder has in respect of this Warrant. The Company shall prepare, issue and deliver at its own expense
any New Warrant under this Section 3.

 

4.                 
Exercise and Duration of Warrant.

 

(a)               
All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by Section 10
of this Warrant at any time and from time to time on or after the Original Issue Date and through and including 5:30 p.m., New
York City time, on the Expiration Date. After 5:30 p.m., New York City time, on the Expiration Date, the portion (or all) of this
Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be automatically terminated
and no longer outstanding.

 

(b)              
The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule
1 hereto (the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price
for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless exercise”
if so indicated in the Exercise Notice and if a “cashless exercise” may occur at such time pursuant to Section 10
below) within one (1) Business Day following the Exercise Date (as defined herein). The date on which the Exercise Notice is delivered
to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.”
No ink-original Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Exercise Notice form be required. The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable
Exercise Price as provided above shall constitute the Holder’s certification to the Company that its representations contained
in Sections B(6), (7), (11), (12), (14) and (16) of the Purchase Agreement are true and correct as of the Exercise Date and as
of the date on which the Holder pays the Company the Exercise Price as if remade in their entirety (or, in the case of any transferee
Holder that is not a party to the Purchase Agreement, such transferee Holder’s certification to the Company that such representations
are true and correct as to such transferee Holder as of the Exercise Date and as of the date on which such transferee Holder pays
the Company the Exercise Price). Notwithstanding anything herein to the contrary, Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
exercised in full, in which case, Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date the final Exercise Notice is delivered to the Company. The Holder shall not be required to deliver the original
Warrant in order to effect an exercise hereunder, but if it is not so delivered then such exercise shall constitute an agreement
by the Holder to deliver the original Warrant to the Company as soon as practicable thereafter. Execution and delivery of the Exercise
Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to
purchase the remaining number of Warrant Shares.

 

    	2

    	 

    

 

5.                 
Delivery of Warrant Shares.

 

Upon exercise of this
Warrant, the Company shall promptly (but in no event later than three Trading Days after the Exercise Date) issue or cause to be
issued and cause to be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate
(provided, that if a Registration Statement covering the resale of the Warrant Shares is not effective and the Holder directs the
Company to deliver a certificate for the Warrant Shares in a name other than that of the Holder or an affiliate of the Holder,
it shall deliver to the Company on the Exercise Date an opinion of counsel reasonably satisfactory to the Company to the effect
that the issuance of such Warrant Shares in such other name may be made pursuant to an available exemption from the registration
requirements of the Securities Act and all applicable state securities or blue sky laws), (i) a certificate for the Warrant Shares
issuable upon such exercise, free of restrictive legends, or (ii) an electronic delivery of the Warrant Shares to the Holder’s
account at the Depository Trust Company (“DTC”) or a similar organization; provided, that if a
Registration Statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not
then effective or the Warrant Shares are not freely transferable without restriction under Rule 144 by Holders who are not affiliates
of the Company, such Holder shall receive a certificate for the Warrant Shares issuable upon such exercise with appropriate restrictive
legends. If the Company fails for any reason to deliver to the Holder certificates evidencing the Warrant Shares or an electronic
delivery of the Warrant Shares by the foregoing deadline, the Company shall pay to the Holder, in cash, as liquidated damages and
not as a penalty, $1,000 per Trading Day for each Trading Day after such delivery deadline until such Warrant Shares are delivered
or Holder rescinds such exercise. The Holder, or any person permissibly so designated by the Holder to receive Warrant Shares,
shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date. Notwithstanding anything contained
herein to the contrary, if the Holder fails to deliver the documents required to register a transferee as set forth in Section
3 above or to provide the documents required under this Section 5(a) to issue a certificate or electronic delivery of
the Warrant Shares to any person(s) other than the Holder, then determination of the three Trading Days shall be tolled until such
documents have been delivered to the Company. If the Warrant Shares are to be issued free of all restrictive legends, the Company
shall, upon the written request of the Holder, use its reasonable best efforts to deliver, or cause to be delivered, the Warrant
Shares hereunder electronically through DTC or another established clearing corporation performing similar functions, if available;
provided, that the Company may, but will not be required to, change its transfer agent if its current transfer agent cannot
deliver the Warrant Shares electronically through such a clearing corporation. “Trading Day” means (a)
a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market (other than the OTCMarkets), or
(b) if the Common Stock is not listed on a Trading Market (other than the OTCMarkets), a day on which the Common Stock is traded
in the over-the-counter market, as reported by the OTCMarkets (or any similar organization or agency succeeding to its functions
of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (a) or (b)
hereof, then Trading Day shall mean a Business Day; provided further, that “Trading Day” shall not include any
day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common
Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does
not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00 p.m., New
York time). “Principal Trading Market” means whichever of the NYSE MKT LLC, the NASDAQ Global Select
Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTCMarkets on which the Common Stock is primarily listed and
quoted for trading. “Trading Market” means whichever of the NYSE MKT LLC, the NASDAQ Global Select Market,
the NASDAQ Global Market, the NASDAQ Capital Market or the OTCMarkets on which the Common Stock is listed or quoted for trading
on the date in question.

 

    	3

    	 

    

 

(a)               
If by the close of the third Trading Day after delivery of a properly completed Exercise Notice and the payment of the aggregate
Exercise Price in any manner permitted by Section 10 of this Warrant, the Company fails to deliver to the Holder a certificate
representing the required number of Warrant Shares in the manner required pursuant to Section 5(a), and if after such third
Trading Day and prior to the receipt of such Warrant Shares, the Holder is required to purchase (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a “Buy-In”), then the Company shall, in its sole discretion,
within three Trading Days after the Holder’s request for payment, either (i) pay in cash to the Holder an amount equal to
the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased,
at which point the number of Warrant Shares underlying this Warrant equal to the number of shares of Common Stock so purchased
shall be forfeited and the Company’s obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate,
or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and
pay cash to the Holder in an amount equal to the excess (if any) of the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased in the Buy-In over the product of (A) the number of shares of
Common Stock purchased in the Buy-In, multiplied by (B) the closing bid price of a share of Common Stock on the Exercise Date.
The Holder shall provide the Company with written notice indicating the amounts payable to the Holder in respect of the Buy-In,
together with applicable confirmations and other evidence reasonably requested by the Company.

 

(b)              
To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with and
subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective
of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery
of any judgment against any person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination,
or any breach or alleged breach by the Holder or any other person of any obligation to the Company (other than breaches related
to this Warrant or the Purchase Agreement) or any violation or alleged violation of law by the Holder or any other person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with
the issuance of Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant
as required pursuant to the terms hereof.

 

    	4

    	 

    

 

6.                 
Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this
Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or
expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided,
however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the
registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an affiliate thereof.
The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant
or receiving Warrant Shares upon exercise hereof.

 

7.                 
Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause
to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a
New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such
case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New
Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then
the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue
the New Warrant.

 

8.                 
Reservation of Warrant Shares. The Company represents and warrants that on the date hereof, it has duly authorized
and reserved, and covenants that it will at all times during the period this Warrant is outstanding reserve and keep available
out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it
to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable
and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of
persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants
that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance
with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable and free from all taxes, liens and
charges created by the Company in respect of the original issuance thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue). The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for
the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company represents and warrants that the Warrant
Shares, when issued and paid for in accordance with the terms of the Purchase Agreement and the Warrants, will be issued free and
clear of all security interests, claims, liens and other encumbrances other than restrictions imposed by applicable securities
laws. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued
as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or
automated quotation system upon which the Common Stock may be listed.

 

    	5

    	 

    

 

9.                 
Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject
to adjustment from time to time as set forth in this Section 9.

 

(a)               
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend
on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock,
(ii) subdivides its outstanding shares of Common Stock into a larger number of shares, (iii) combines (by combination, reverse
stock split or otherwise) its outstanding shares of Common Stock into a smaller number of shares (a “Stock Combination
Event”), or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company,
then in each such case the Exercise Price shall be adjusted to a price determined by multiplying the Exercise Price in effect immediately
prior to the effective date of such event by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding
on such effective date immediately before giving effect to such event and the denominator of which shall be the number of shares
of Common Stock outstanding immediately after giving effect to such event. Any adjustment made pursuant to clause (i) of this paragraph
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution, and any adjustment pursuant to clause (ii), (iii) or (iv) of this paragraph shall become effective immediately
after the effective date of such subdivision, combination or reclassification.

 

(b)              
Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders
of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common
Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other
asset, including cash (in each case, “Distributed Property”), except for any distributions pursuant to
a shareholders’ rights plan or similar takeover defense agreement or plan adopted by the Company, then, upon any exercise
of this Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution,
the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable),
the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the
Holder been the record holder of such Warrant Shares immediately prior to such record date.

 

    	6

    	 

    

 

(c)               
Fundamental Transactions. If, at any time while this Warrant is outstanding (i) the Company effects (A) any merger
of the Company with (but not into) another person, in which stockholders of the Company immediately prior to such transaction own
less than a majority of the outstanding stock of the surviving entity, or (B) any merger or consolidation of the Company into another
person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions,
(iii) any tender offer or exchange offer approved or authorized by the Company’s Board of Directors is completed pursuant
to which holders of at least a majority of the outstanding Common Stock tender or exchange their shares for other securities, cash
or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to
which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result
of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental
Transaction”), then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same
amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental
Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then
issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the “Alternate
Consideration”), and the Holder shall no longer have the right to receive Warrant Shares upon exercise of this Warrant.
The Company shall not effect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof,
any successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate
corporation or person shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with
the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of
this paragraph (c) shall similarly apply to subsequent transactions of an analogous type to any Fundamental Transaction.

 

(d)              
Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to paragraph (a) or (f)
of this Section 9, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or
decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased
number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

(e)               
Anti-Dilution. Protection. In the event that at any time prior to the date that is eighteen months from the date
hereof, the Company issues any securities in a capital-raising transaction that include a price-based anti-dilution adjustment
provision, such price-based anti- dilution adjustment provision shall be deemed automatically incorporated into this Warrant.
Promptly following such incorporation, the Company and the Holder shall amend this Warrant to formally incorporate such provision
herein.

 

(f)               
Calculations. All calculations under this Section 9 shall be made to the nearest cent or the nearest share,
as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or
for the account of the Company.

 

    	7

    	 

    

 

(g)              
Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its
expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms
of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and
adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing
the transactions giving rise to such adjustments and showing in reasonable detail the facts upon which such adjustment is based.
Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s
transfer agent.

 

(h)              
Notice of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting
of rights or warrants to subscribe for or purchase any capital stock of the Company, (ii) authorizes or approves, enters into any
agreement contemplating or solicits stockholder approval for any Fundamental Transaction, or (iii) authorizes the voluntary dissolution,
liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to
constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10)
Business Days prior to the applicable record or effective date on which a person would need to hold Common Stock in order to participate
in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein
shall not affect the validity of the corporate action required to be described in such notice.

 

10.             
Payment of Exercise Price. The Holder shall pay the Exercise Price in immediately available funds; provided, however,
that if, on any Exercise Date there is not an effective Registration Statement registering, or no current prospectus available
for, the resale of the Warrant Shares by the Holder, then the Holder may, in its sole discretion, satisfy its obligation to pay
the Exercise Price through a “cashless exercise”, in which event the Company shall issue to the Holder the number of
Warrant Shares determined as follows:

 

X = Y[(A-B)/A]

 

where:

 

X = the number of Warrant
Shares to be issued to the Holder.

 

Y = the total number
of Warrant Shares with respect to which this Warrant is being exercised.

 

A = the average of
the Closing Bid Price of the shares of Common Stock (as reported by Bloomberg Financial Markets) for the five consecutive Trading
Days ending on the date immediately preceding the Exercise Date.

 

B = the Exercise Price
then in effect for the applicable Warrant Shares at the time of such exercise.

 

    	8

    	 

    

 

For purposes of this
Warrant, “Closing Bid Price” means, for any security as of any date, the last reported closing bid price
for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal
Trading Market begins to operate on an extended hours basis and does not designate the closing bid price, then the last bid price
of such security prior to 4:00 p.m., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not
apply, the last closing price of such security in the over-the-counter market on the electronic bulletin board for such security
as reported by Bloomberg Financial Markets, or, if no closing bid price is reported for such security by Bloomberg Financial Markets,
the average of the bid prices of any market makers for such security as reported on OTC Pink (also known as the “pink sheets”)
by the OTCMarkets. If the Closing Bid Price cannot be calculated for a security on a particular date on any of the foregoing bases,
the Closing Bid Price of such security on such date shall be the fair market value as mutually determined by the Company and the
Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors
of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors’ determination
shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock
dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

For purposes of Rule
144, it is intended, understood and acknowledged that the provisions above permitting “cashless exercise” are intended,
in part, to ensure that a full or partial exchange of this Warrant pursuant to such provisions will qualify as a conversion, within
the meaning of paragraph (d)(3)(ii) of Rule 144, and the holding period for the Warrant Shares shall be deemed to have commenced
as to such original Holder, on the Original Issue Date.

 

11.             
Limitations on Exercise. Notwithstanding anything to the contrary contained herein, the number of Warrant Shares
that may be acquired by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the extent
necessary to ensure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially
owned by the Holder and its affiliates and any other persons whose beneficial ownership of Common Stock would be aggregated with
the Holder’s for purposes of Section 13(d) of the Exchange Act, does not exceed 4.99% of the total number of then issued
and outstanding shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise). For
purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and its affiliates
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination
of such sentence is being made, but shall exclude the number of shares of Common Stock which are issuable upon (a) exercise of
the remaining, unexercised portion of this Warrant beneficially owned by such person and its affiliates and (b) exercise or conversion
of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates
(including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion
or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, beneficial ownership shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to such Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and such Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 11 applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by such Holder) and of which portion of this Warrant is exercisable shall be in the sole
discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of
whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which portion of this Warrant
is exercisable, in each case subject to such aggregate percentage limitation, and the Company shall have no obligation to verify
or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 11, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of
outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may
be, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth
the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three Trading
Days confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities
of the Company, including this Warrant, by the Holder and its affiliates since the date as of which such number of outstanding
shares of Common Stock was last publicly reported or confirmed to the Holder. This provision shall not restrict the number of shares
of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration
that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9 of this Warrant. By
written notice to the Company, which will not be effective until the 61st day after such notice is delivered to the Company, the
Holder may waive the provisions of this Section 11 (but such waiver will not affect any other holder) to change the beneficial
ownership limitation to 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon exercise of this Warrant, and the provisions of this Section 11 shall continue to apply.
Upon such a change by a Holder of the beneficial ownership limitation from such 4.99% limitation to such 9.99% limitation, the
beneficial ownership limitation may not be further waived by such Holder.

 

    	9

    	 

    

 

12.             
No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant.
In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down
to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Bid Price) for
any such fractional shares.

 

13.             
Notices. Any notice or other document required or permitted to be given or delivered to the Purchasers shall be in
writing and sent (a) by fax if the sender on the same day sends a confirming copy of such notice by an internationally recognized
overnight delivery service (charges prepaid) or (b) by an internationally recognized overnight delivery service (with charges prepaid).
The address and facsimile number of a person for such notices or communications shall be as set forth in the Purchase Agreement
unless changed by such person by two Trading Days’ prior notice to the other person(s) in accordance with this Section
13.

 

14.             
Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon 15 days’ notice to the Holder,
the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any
corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation
to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business
shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly
cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s
last address as shown on the Warrant Register.

  

15.             
Miscellaneous.

 

(a)               
No Rights as a Stockholder. The Holder, solely in such person’s capacity as a holder of this Warrant, shall
not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant be construed to confer upon the Holder, solely in such person’s capacity as the Holder
of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate
action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the
Holder of the Warrant Shares which such person is then entitled to receive upon the due exercise of this Warrant. In addition,
nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities, whether
such liabilities are asserted by the Company or by creditors of the Company.

 

    	10

    	 

    

 

(b)              
Authorized Shares.

 

(i)                
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as
provided herein without violation of any applicable law or regulation or of any requirements of the Principal Trading Market upon
which the Common Stock may be listed.

 

(ii)              
Except and to the extent waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issuance or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of the Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (1) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in par value, (2) take all such action as may be
necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon
the exercise of this Warrant, and (3) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations
under this Warrant.

 

(iii)            
Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable
or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

(c)               
Successors and Assigns. Subject to the restrictions on transfer set forth in this Warrant and in Sections B(7) and
(8) of the Purchase Agreement, and compliance with applicable securities laws, this Warrant may be assigned by the Holder. This
Warrant may not be assigned by the Company without the written consent of the Holder except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding upon and inure to the benefit of the Company and the Holder and their respective heirs,
estate, legal representatives, successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed
to give to any person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this
Warrant.

 

    	11

    	 

    

 

(d)              
Amendment and Waiver. Except as otherwise provided herein, the provisions of this Warrant may be amended and the
Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company
has obtained the written consent of the Holder.

 

(e)               
Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms
and conditions contained herein.

 

(f)               
Governing Law. This Warrant shall be enforced, governed and construed in all respects in accordance with the laws
of the State of New York, as such laws are applied by the New York courts to agreements entered into and to be performed in New
York by and between residents of New York.

 

(g)              
Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be
deemed to limit or affect any of the provisions hereof.

 

(h)              
Severability. If any provision of this Warrant is held to be invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed modified to conform with such statute or rule of law. Any provision hereof
that may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provisions hereof.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	12

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	TRANSGENOMIC, INC.	 
	 	 	 	 
	 	By:	 	 
	 	 Name:	Paul Kinnon	 
	 	Title: 	President and Chief Executive Officer	 

  

    	[Signature Page to Warrant]

    	 

    

 

SCHEDULE 1

TRANSGENOMIC, INC.

FORM OF EXERCISE NOTICE

[To be executed by the Holder to purchase shares of Common Stock under the Warrant]

 

Ladies and Gentlemen:

 

(1)              
The undersigned is the Holder of Warrant No. __________ (the “Warrant”) issued by Transgenomic,
Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not otherwise defined
herein have the respective meanings set forth in the Warrant.

 

(2)              
The undersigned hereby exercises its right to purchase __________ Warrant Shares pursuant to the Warrant.

 

(3)              
The Holder intends that payment of the Exercise Price shall be made as (check one):

 

	 	 ̈	Cash Exercise
	 	 	 
	 	 ̈	“Cashless Exercise” under Section 10 of the Warrant
	 	 	 

(4)              
If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $_______ in immediately available funds to the
Company in accordance with the terms of the Warrant.

 

(5)              
Pursuant to this Exercise Notice, the Company shall deliver to the Holder’s Warrant Shares determined in accordance
with the terms of the Warrant. Please issue (check applicable box):

 

	 	 ̈	A certificate of certificates representing the Holder’s Warrant Shares in the name of the undersigned or in such other name as is specified below:
	 	 
	.	 ̈	The Holder’s Warrant Shares in electronic form to the following account:
	 	 
	 	
        Name and Contact for Broker:

         

	 	
        Broker no:

         

	 	
        Account no:

         

	 	
        Account holder: 

 

    	 

    	 

    

 

(6)              
By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to
the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined
in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11 of
the Warrant to which this notice relates.

 

(7)              
By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that its representations
contained in Sections B(6), (7), (11), (12), (14) and (16) of the Purchase Agreement are true and correct as of the Exercise Date
and as of the date on which the Holder pays the Company the Exercise Price as if remade in their entirety (or, in the case of any
transferee Holder that is not a party to the Purchase Agreement, such transferee Holder represents and warrants to the Company
that such representations are true and correct as to such transferee Holder as of the Exercise Date and as of the date on which
such transferee Holder pays the Company the Exercise Price).

 

Dated: _______________, _____

 

Name of Holder: ____________________________

 

By: ______________________________________

Name:

Title:

 

(Signature must conform in all respects
to name of Holder as specified on the face of the Warrant)

 

    	 

    	 

    

 

SCHEDULE 2

TRANSGENOMIC, INC.

FORM OF ASSIGNMENT

[To be completed and executed by the Holder only upon transfer of the Warrant]

 

FOR VALUE RECEIVED,
the undersigned hereby sells, assigns and transfers unto ______________ (the “Transferee”) the right
represented by the within Warrant to purchase _____________ shares of Common Stock of Transgenomic, Inc., a Delaware corporation
(the “Company”) to which the within Warrant relates and appoints ___________ attorney to transfer said
right on the books of the Company with full power of substitution in the premises. In connection therewith, the undersigned represents,
warrants, covenants and agrees to and with the Company that:

 

		(a)	the offer and sale of the Warrant contemplated hereby is being made in compliance with Section
4(1) of the United States Securities Act of 1933, as amended (the “Securities Act”), or another valid
exemption from the registration requirements of Section 5 of the Securities Act and in compliance with all applicable securities
laws of the states of the United States;

 

		(b)	the undersigned has not offered to sell the Warrant by any form of general solicitation or general
advertising, including, but not limited to, any advertisement, article, notice or other communication published in any newspaper,
magazine or similar media or broadcast over television or radio, and any seminar or meeting whose attendees have been invited by
any general solicitation or general advertising;

 

		(c)	the undersigned has read the Transferee’s investment letter included herewith (as required
by Section 3(b) of the Warrant), and to its actual knowledge, the statements made therein are true and correct; and

 

		(d)	the undersigned understands that the Company may condition the transfer of the Warrant contemplated
hereby upon the delivery to the Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel
(which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect
that such transfer may be made without registration under the Securities Act and under applicable securities laws of the states
of the United States.

 

Dated: ___________, _____

______________________________________________________________

(Signature must conform in all respects to name of holder as specified on the face of the Warrant)

 

In the presence of:                                                             Address of Transferee:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]